Back to Search
JEROME ARMAND, M.D.
M.D.
Neonatal-Perinatal Medicine Physician
NPI: 1215990361Individual
Specialties, Licenses & Credentials
Neonatal-Perinatal Medicine PhysicianPrimary
Pediatrics — Neonatal-Perinatal Medicine
Code: 2080N0001X
019138(GA)
Research & Publications (20)
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
PMID 17405892·Oncologist·2007
6-review
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
PMID 19352594·Invest New Drugs·2010
5-case
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
PMID 19204207·J Clin Oncol·2009
3-trial
Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.
PMID 19386436·Int J Radiat Oncol Biol Phys·2009
8-other
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
PMID 19541476·Eur J Cancer·2009
3-trial
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.
PMID 18349858·Nat Clin Pract Oncol·2008
6-review
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.
PMID 18042834·Ann Oncol·2008
1-meta
Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors.
PMID 18360630·Ther Clin Risk Manag·2007
8-other
Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
PMID 17065198·Carcinogenesis·2007
8-other
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
PMID 17363536·Clin Cancer Res·2007
3-trial
QTc monitoring during a phase I study: experience with SR271425.
PMID 17414458·Am J Clin Oncol·2007
3-trial
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
PMID 17616683·Cancer Res·2007
8-other
Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy.
PMID 17018743·Ann Oncol·2006
6-review
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
PMID 16763786·Invest New Drugs·2006
3-trial
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
PMID 16314617·J Clin Oncol·2006
3-trial
New concepts for phase I trials: evaluating new drugs combined with radiation therapy.
PMID 16264990·Nat Clin Pract Oncol·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2701 N DECATUR RD
DECATUR, GA 30033 - Phone
- (404) 501-1843
Quick Facts
- NPI
- 1215990361
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile